CD274 and non-small cell lung carcinoma: For nivolumab, improved OS, PFS and response rates are seen in NSCLC patients with lower thresholds for PD-L1 expression (≥1%, ≥5%, and ≥ 10%) as evident from the CheckMate 017 and CheckMate 057 studies which compared nivolumab monotherapy to docetaxel in the second-line setting [12–14].